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Predictive value of vascular endothelial growth factor
(VEGF) in metastasis and prognosis of human colorectal
cancer
S-1 Ishigami, S Arii, M Furutani, M Niwano, T Harada, M Mizumoto, A Mori, H Onodera and M Imamura
First Departnent of Surgery. Faculty of Medkcine. Kyoto University. Kyoto. Japan
Summary Vascular endothelial growth factor (VEGF) may affect the phenotype of cancer cells, such as growth velocity and metastatic
potential, due to its probable multifunctional property including a mitogenic activity for vascular endothelial cells. The present study was
designed to investigate the association of VEGF mRNA expression with progression and metastasis of human colorectal cancer. The level of
VEGF mRNA expression was quantified by Northem blot hybridization in tumorous and non-tumorous tissues obtained from 60 primary
colorectal cancer patients. The ratio of the former to the latter was defined as the VEGF T/N ratio, and the prognostic significance of this ratio,
following surgery, in addition to the relationship to progression and metastatic potential, was evaluated. The value of the VEGF T/N ratio was
significantly correlated with the depth of tumour infiltration (P = 0.046), the incidence of liver metastasis (P < 0.0001) and lymph node
metastasis (P = 0.036). Patient prognosis was estimated by the Kaplan-Meier method and the log-rank test. When the VEGF T/N ratio was
higher than 4.8 for which the X2 value of the log-rank test was maximal, the tumour was defined as showing overexpression of VEGF mRNA.
Patients with overexpression of VEGF mRNA demonstrated poorer survival than patients without overexpression of VEGF mRNA
(P < 0.001). The overall estimated hazard ratio for death in patients with overexpression of VEGF mRNA was 1.94 according to a multivariate
analysis (P = 0.005). Thus, VEGF is associated with the progression, invasion and metastasis of colorectal cancer, and overexpression of
VEGF mRNA in the primary tumour is assumed to be closely correlated with poor prognosis in colorectal cancer patients. Moreover, the
VEGF T/N ratio may be used as an independent prognostic marker in colorectal cancer patients.
Keywords: colorectal cancer; the vascular endothelial growth factor tumorous/non-tumorous tissue ratio; overexpression of vascular
endothelial growth factor mRNA; metastatic potential: Cox's proportional hazard model
Vascular endothelial erowth factor (VEGF) w-as discovered in
1983. and first called xascular permeability factor (VPF) (Senger
et al. 1983). In 1989. a growth factor specific for Xascular endothe-
lial cells was purified form the media conditioned by box ine pitu-
itarv follicular stellate cells. and this factor was named VEGF
(Ferrara et al. 1989).
Recent studies haxe demonstrated that VEGF is strongiv
expressed in several human solid tumours. and its expression is
correlated xith the density of microxessels in tumours of the
kidney (Takahashi et al. 1994). breast (Toi et al. 1994). brain
(Berkman et al. 1993: Samoto et al. 1995). colon (Takahashi et al.
1995: Takahashi et al. 1997). stomach (Maeda et al. 1996). lung
(Mattern et al. 1996). oesophagus (Inoue et al. 1997) and liver
(Mise et al. 1996). Concerning VEGF expression in colorectal
cancer tissues. Broxn et al (1993) first described that the malih-
nant epithelial cells strongly expressed VEGF mRNA in contrast
to normal epithelium by in situ hbnridization. and that tumour cells
stained stronalv for VEGF protein by immunohistochemistrx
(Brown et al. 1993). Furthermore. experimental studies haxe
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shoxxn that tumours wxith high expression of VEGF grewx rapidls
(Ferrara et al. 1993: Kondo et al. 1993) and exhibited metastatic
abilitx (Asano et al. 1995: Warren et al. 1995). However. verv fex
clinical in estigations have been reported regarding the correlation
bet-een VEGF and the progression of colorectal cancer.
Takahashi et al (1995) showed that VEGF expression at protein
lex el detected bv immunohistochemistry x as correlated with
xvessel count in the tumour and metastasis. and mav be useful for
predicting distant recurrence in patients with node-negatixe colon
cancer (Takahashi et al. 1997). Howexer. thev did not make clear
the correlation betxween VEGF expression and hepatic or lNmph
node metastasis.
In the present study. we directed our attention to the relationship
among VEGF mRNA expression w-ith Northern blot analysis.
clinicopathological xariables. including hepatic and lymph node
metastasis. and survival with prospective study.
Northern blot analysis is thought to provide a more objectixe
quantification than immunohistochemical study and w-e preferred
this method to immunohistochemistrv. Moreoxer. considerinn, that
biolooical activities of VEGF are not merely induction of anaio-
genesis (Gabrilovich et al. 1996: Tsurumi et al. 1997: van der Zee
et al. 1997) we focused on VEGF mRNA expression itselfwxithout
study ina the correlation with number ofv-essels in the tumour.
Exvidence will be presented indicatina that VEGF mRNA
expression plays a predictive role in the prognosis and the hepatic
and lymph node metastasis ofcolorectal cancer patients.
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Table 1 Correlations between VEGF mRNA expression and
clinicopathological parameters
Patients VEGF expression
Parameter No. % Mean s.d. Range ttest P-valueb
Sex
Male 40 66.7 4.74 5.02 0.57-23.85
Female 20 33.3 2.59 3.91 0.67-18.63 1.680 NS (0.100)
Age (years)
<60 18 30.0 3.59 4.20 0.69-18.63
>60 42 70.0 4.21 + 5.02 0.57-23.85 0.461 NS (0.646)
Tumour location
Colon 31 51.7 3.82 4.12 0.57-20.58
Rectum 29 48.3 4.24 5.42 0.69-23.85 0.339 NS (0.736)
Tumour size (cm)
< 5.0 30 50.0 3.46 + 3.96 0.57-20.58
> 5.0 30 50.0 4.59 5.45 0.84-23.85 0.914 NS (0.365)
Depth of infiltration
.pmc 17 28.3 2.08 + 1.29 0.57-4.57
>pm 43 71.7 4.79 - 5.39 0.69-23.85 2.043 0.046
Tumour differentiation
Well 19 31.7 2.92 - 2.72 0.57-12.07
Moderate 41 68.3 4.54 5.40 0.67-23.85 1.228 NS (0.224)
Lymphatic invotvement
1y (-) 3 5.0 2.01 0.32 1.38-2.44
Iy (+) 57 95.0 4.13 23.60 0.57-23.85 0.749 NS (0.457)
Vascular invotvement
v (-) 9 15.0 1.73 0.22 0.57-2.44
v(+) 51 85.0 4.43_-25.52 1 03-23.85 1.589 NS (0.118)
Liver metastasis
(synchronous)
H (-) 45 75.0 2.57 1.98 0.57-8.68
H(+) 15 25.0 8.39 7.48 1.03-23.85 4.813 P< 0.0001
Lymph node metastasis
N (-) 27 45.0 2.61 - 3.75 0.57-20.58
N (+) 33 55.0 5.18 5.22 0.69-23.85 2.142 0.036
Dukes' stage
A 13 21.7 2.10 1.25 0.57-4.57 0.019c
B 10 16.7 1.86 1.01 0.94-3.68 0.018'
C 19 31.7 3.12 2.54 0.69-8.68 0.015'
D 18 30.0 7.57 +7.09 1.03-23.85
aUnpaired t-test was used forcomparison of two groups. rA two-tailed
P-value < 0.05 was considered to indicate statistical significance. cTumour
infiltration is confined to the proprial muscularis Layer of the mucosa. dThe
P-value against Dukes' D cases. NS, not significant.
MATERIALS AND METHODS
Human samples and clinicopathological data
Sixty primary colorectal cancer specimens were obtained from 60
patients (40 men and 20 women: age range. 43-90years: mean age
65.3 vears) who had undergone surgery from April 1994 to Julv
1996 in the First Department of Surgery. Facultv of Medicine. at
the Kyoto Unixersity Hospital. Patients' profiles are histed in Table
1. Except Dukes' A cases. these patients Nx-ere uniformly gixven
post-operative adjuvant chemotherapy Awith oral administration of
anti-cancer agents of fluorouracil type. None of the patients
received irradiation or chemotherapy before surgery.
After the remoxal of necrotic tissue. tumorous tissue and adja-
cent normal mucosa without the underlying muscularis layer were
collected. Ahole tumorous tissue w-as divided into tw-o pieces.
One specimen was frozen immediately and stored at -80 C until
processing. and the other was fixed for the purpose ofhistopatho-
logical examination. After checkinc the distribution ofcancer cells
and stromal cells. RNA extraction was performed. Consequently.
there was no apparent difference in their distribution among all
specimens. probably because ofthe similargrade ofdifferentiation
of cancers. The clinical features of these patients were noted with
reference to clinical reports and pathology reports. includinc
Dukes' clinical classification. histological tvpe. lixer metastasis.
lyvmph node metastasis. lymphatic involvement and Xascular
involvement of the disease. Haematoxvlin and eosin (H&E)
stainingx was routinely performed to determine histologrical type.
lymphatic Mix-olvement and vascular involvement in all cases. In
1 cases in which lymphatic involxvement or Xascular involxvement
was diagnosed to be negatixe by H&E staining. Elastica Van
Gieson staining w-as performed to revaluate them.
Preparation of RNA from human samples
Guanidine isothiocvanate (GTC) and caesium chloride were
purchased from Wako Pure Chemical Industries (Japan). Oligotex-
dT3O(Super) was purchased from JSR Corporation (Japan). Tissue
specimens were crushed in liquid nitrogen. and homogenized with
4 s GTC containing 25 mmi sodium citrate (pH 7.0). 0.5%7 lauroxl
sarcosine and 0.1 m -mercaptoethanol. The tissue homogenate
wxas then layered over 5.7 \t caesium chloride containing 0.01 m
disodium EDTA (pH 7.0). and ultracentrifuged at 180 000g at
20CC for 15-18 h. Pellets. which wxere located at the bottom ofthe
centrifutation tubes. were collected and total cytoplasmic RNA
was extracted using the phenol-chloroform method (Sambrook et
al. 1989). Poly(A)+ RNA was purified from total RNA usingy
Oligotex-dT3O(Super) according to the method described previ-
ously (Kuribayashi et al. 1988).
DNA probes for Northern blot analysis
The DNA probe for human VEGF 164 protein wxas prepared as
followxs: 5 jg¢ of human liver total RNA was reverse transcribed
wxith random primers. using a commercial kit (First Strand
Synthesis Kit: Phannacia. Piscataway. NJ. USA). The resulting
complementary DNA (cDNA) mixture was subjected to 30 cycles
(1 mmn at 94CC. 1 min at 55CC and 1 mmn at 72 C) of polvrmerase
chain reaction (PCR) amplification using a DNA thermal cycler
(Aster. Japan). Taq DNA polymerase (Toyobo. Japan) and specific
VEGF primers. The following oligonucleotide primers. wxhich
were based on the human VEGF cDNA sequence. were used
(Tischer et al. 1991): 'sense pnrmer'. 5'-TTGCTGCTCTAC-
CTCCAC-3'; 'antisense pnrmer'. 5'-AATGCTTICTCCGCTCTG-
3'. Two kinds of PCR products. consisting of 418 bp and 490 bp.
encoding VEGF,65 and VEGFI. respectixely. wxere obtained. The
PCR product that encoded VEGF 6, was cloned into the EcoRV
site of the pBluescript SK(-) plasmid. and the insert Aas
confirmed by sequencing (Marchuk et al. 1991). The insert was
purified and used as a probe in Northern blot analysis.
Northem blot analysis
Hvbond-N nvlon membrane. Rapid-hybridization buffer and the
Megapnrme DNA labelling kit were purchased from Amersham
British Joumal ofCancer (1998) 78(10), 1379-1384 0 Cancer Research Campaign 1998VEGFgene expression in human colorectal cancer 1381
' t '1 t t* t ~~~~~~~(3.7 d3)
._w- ~~~~~~~~~~S26 rpmRNA
N T NI T N T N T N T N T N T
Li Li Li Li Li Li Li
Figure 1 VEGF mRNA expression in colorectal cancer. Poly-A- RNA (5 ug)
was electrophoresed on a 1.0% agarose gel, and then transferred to a
Hybond-N- nylon membrane. Blotted membranes were hybridized using
[a-32P1dCTP-labelled human VEGF165 cDNA. and the same membrane was
rehybridized using S26 ribosomal protein cDNA. The expression of 3.7-kb
VEGF mRNA transcript was detected in both tumorous tissue and adjacent
normal mucosa. N. normal colon mucosa; T. tumour; S26rp, S26 ribosomal
protein
Lifescience (UK). [ax-'P]dCTP wxas purchased from ICN
Biomedicals (USA). Polv-A mRNA (5 at) was electrophoresed
on a 1.0%c agarose gel containing 2.2 m formaldehyde in 1 x 3 (N-
morpholino) propanesulphonic acid (MOPS) buffer (20 mmx
MOPS. 5 mm sodium acetate. 1 mM EDTA-2Na]. and then trans-
ferred to a Hybond-N- nylon membrane by capillary blotting.
followed by ultraviolet (UV) cross-linkage. Blotted membranes
were prehybridized in Rapid-hybridization buffer at 65CC for
30 mmn. [a- P]dCTP-labelled human VEGF16 cDNA wxas
prepared using a Megaprime DNA labelling kit. If the radioac-
tivitv in the reaction buffer x-as high. a Sephadex-G column xxas
used to remove free radioisotopes. Hybridization was performed at
65CC for 2 h and then the membranes were x-ashed twice for 10
mmn at room temperature in 2 x standard saline citrate (SSC) (300
mist sodium chloride. 30 nm¶ sodium citrate) with 0.1% sodium
dodecyl sulphate (SDS). When background radioactivity was high.
membranes were xashed again at 653C for 20 min in 1 x SSC with
0.1% SDS. and then at 653C for 15 min in 0.1 x SSC xxith 0.1%7
SDS. Membranes were exposed to Konica X-ray films at -80-C
for appropriate intervals. The membranes were rehybridized with
S26 ribosomal protein (S26rp) DNA probe as an intemal control.
All techniques were performed according to standard methods
described previously (Sambrook et al. 1989). The level of VEGF
miRiNA expression was quantified by densitometric analysis using,
Densitograph. Ver.4.0 (ATTO. Japan) in tumorous and non-
tumorous tissues. and as normalized to S26rp mRNA expression.
The ratio of the former to the latter was defined as the VEGF T/N
ratio. and the prognostic significance after surgery and the rela-
tionship to metastatic potential ere evaluated.
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Figure 2 Kaplan-Meier overall survival curves of 56 colorectal cancer
patients after surgery. When the cut-off point of the VEGF T/N ratio ranged
from 2.8 to 12.0, the difference between survivors and non-survivors was
statistically significant. To determine the optimal cut-off point of the VEGF T/N
ratio. the analytca method based on which X2 value of the log-rank test was
maximal was used. As a result. 4.8 was established as the optimal cut-off
point for the VEGF TIN ratio, and tumours with this ratio exceeding 4.8 were
defined as showing overexpression of VEGF mRNA. The patients with
overexpression of VEGF mRNA demonstrated poorer survival than the
patients witout overexpression of VEGF mRNA, by both the log-rank test
(P< 0.001) and the Wilcoxon test (P= 0.0002)
Correlation among VEGF mRNA expression,
clinicopathological variables and survival
The correlation between VEGF mRNA expression and clinico-
pathological variables was analysed statistically using the
unpaired t-test for comparisons of tu-o groups. Almost all of the
patients were followed for approximately 3 years after surgery. and
patients outcome was ascertained in 56 out of 60 cases. Survival
was calculated from the date ofoperation to the date ofdeath or of
the last follow--up. and the median follow-up term for the patients
Aithout cancer death was 30.1 months. Survival rate x as estimated
by the Kaplan-Meier method. and statistical significance was
compared using the log-rank test and the Wilcoxon test. Unixariate
and multixariate analyses were performed usinr Cox's regression
model to determine the actual role of VEGF in patient prognosis.
To determine the optimal cut-off point of the VEGF T/N ratio.
an analytical method prexiouslv reported was used (Miller and
Siegmund. 1982). When the VEGF T/N ratio xas higher than 4.8.
for which the X xvalue of the log-rank test wxas maximal. we
defined such a tumour as showing oxerexpression of VEGF
mRNA. JMP-3.1.5 softwxare (SAS Institute. Can'. NC. USA) and
Stat View-J 4.5 software (Abacus Concepts. Berkelev. CA. USA)
were used for the analyses. and P < 0.05 A-as considered to be
statistically sirnificant.
Table 2 Cox's multivanate proportional hazard model for survival
Univariate analysis Multivariate analysis
Variable Risk ratio 95% CP P Risk ratio 95% CP P
The VEGF T/N ratio (< 4.8. >4.8) 2.49 1.61-3.85 < 0.0001 1.94 1.23-3.06 0.005:
Depth of tumour infiltration (spm, >pm) 3.55 1.30-9.72 0.013C 2.54 0.88-7.30 0.084
Maximum diameter (<5.0 cm. >5.0 cm) 0.75 0.49-1.16 0.195 0.81 0.52-1.26 0.350
Tumour differentiation (well, moderate) 1.88 1.02-3.47 0.043: 1.21 0.63-2.30 0.565
aCl. confidence interval. Pvalue < 0.05 was considered to indicate statistical significance.
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RESULTS
VEGF mRNA expression in colorectal cancer
Five VEGF mRNA splicing variants. which encoded 121, 145
(Poltorak et al, 1997). 165. 189 and 206 (Houck et al. 1991) amino
acids respectively were produced from a single gene as a result of
alternative splicing. The cDNA encoding VEGF165, which is a
major isoform ofthis protein, was used for Northem blot analysis.
Representative cases of Northern blot hybridization are shown in
Figure 1. The expression of 3.7-kb VEGF mRNA transcript was
detected in both tumour and adjacent normal mucosa, and the
VEGF T/N ratio in these cases ranged from 0.57 to 23.85. Fifty-
twoof60 (86.7%) patients hadhigherexpression in tumourthan in
non-cancerous mucosa, and in eight cases the VEGFT/N ratio was
less than 1.
Association of the VEGF T/N ratio with patient profile,
and clinixpathological variables
The association of VEGF mRNA levels with clinicopathological
variables is demonstrated in Table 1. No significant correlation
was observed between the levels ofVEGF T/N ratio and sex, age.
location, size, tumour differentiation, lymphatic involvement or
vascular involvement The VEGFT/N ratio in Dukes' D cases was
significantly higher than those in Dukes' A (P = 0.019), Dukes' B
(P = 0.018) and Dukes' C (P = 0.015) cases, but no difference was
observed among Dukes' A. B and C cases. This ratio was signifi-
cantly correlated with the depth of tumour infiltration (P = 0.046).
Furthermore, VEGF mRNA expression was significantly higher in
tumours with lymph node metastasis (5.18 ± 5.22) than in those
without (2.61 + 3.75, P = 0.036). The mean ± s.d. of VEGF
gene expression in cases with synchronous liver metastasis
(8.39 ± 7.48) was significantly higher than in cases without
(2.57 ± 1.98,P <0.0001).
Patient prognosis
During the follow-up term. 21 patients died as a result of
recurrence (10 of 11 patients with overexpression of VEGF
mRNA. and 11 of 45 patients without overexpression of VEGF
mRNA). To define the significance of the VEGF T/N ratio as an
independent prognostic marker, four variables (the VEGF T/N
ratio, tumour size, depth of tumour infiltration and tumour differ-
entiation), which reflect malignant potential of the primary
tumour, were selected. and both univariate and multivariate
analysis were performed using Cox's regression model (Table 2).
According to univariate analysis, overexpression ofVEGF mRNA
(P < 0.0001), depth of tumour infiltration (P = 0.013) and tumour
differentiation (P = 0.043) were associated with poor overall
survival of colorectal cancer patients. Multivariate analysis
demonstrated that the overall estimated hazard ratio for death in
patients with overexpression of VEGF mRNA was 1.94 (95%
confidence interval, 1.23-3.06, P =0.005). and that the VEGFT/N
ratio was the most significant prognostic marker for overall
survival among these variables. Survival rates ofthese 56 patients
with or without overexpression of VEGF mRNA are shown in
Figure 2. One-, 2- and 3-year survival rates ofthe patients without
overexpression of VEGF mRNA were 86.7. 77.4 and 74.9%
respectively, whereas 1- and 2-year survival rates of the patients
with overexpression of VEGF mRNA were 54.5 and 18.2%
respectively. The patients with overexpression of VEGF mRNA
demonstrated poorer survival than the patients without over-
expression ofVEGF mRNA by both the log-rank test (P < 0.001)
and the Wllcoxon test (P = 0.0002).
DISCUSSION
Multistep carcinogenesis in colon cancer is a well-recognized
mechanism that was originally proposed by Vogelstein et al
(1988). However, no clear explanation has been provided at the
molecular level of invasion or metastasis following carcinogen-
esis. Recent investigations have suggested possible participants in
the metastatic potential ofcancercells such as adhesion molecules,
proteinases, angiogenic factors, etc. In the present study, we
directed our attention to an angiogenic molecule. VEGF. which is
the most potent mitogen specific for vascular endothelial cells.
mainly because angiogenesis seems to be a prerequisite for the
growth ofsolid tumours.
Many reports have shown acorrelation between neovasculariza-
tion in tumours and VEGF expression. indicating the important
role of VEGF in tumour angiogenesis. However, VEGF has some
different functions from mitogenic activity for vascular endothe-
lial cells (Gabrilovich et al, 1996; Tsurumi et al, 1997: van derZee
et al. 1997). and we thus attempted to evaluate the association of
VEGF mRNA expression with the progression of colorectal
cancer apart from its angiogenic role. The reason we chose the
VEGF mRNA as a determinant, but not VEGF protein. was that
Northern blot analysis is more objective as a quantitative measure-
ment than the immunohistochemical method.
The results here demonstrated that the expression of VEGF
mRNA was highest in the Dukes' D class, representing those
tumours with either extended lymph node metastasis, liver metas-
tasis or peritoneal dissemination. Actually, higher expression of
VEGF mRNA in the primary tumours was observed in the pres-
ence of lymph node involvement or hepatic metastasis than in
those without. Moreover, VEGF gene expression in the tumour
tended to be augmented as the severity of cancer involvement in
the vasculolymphatic system increased (data not shown).
VEGF may play a broader role in the biological and patho-
logical characteristics ofcancer than was previously thought. The
rationale for the participation of VEGF in the metastatic potential
of tumours may be as follows. First, an increase in the microvas-
cular density of tumours may increase the probability that cancer
cells break loose into the circulatory system. The development of
vascular networks possibly leads to increases in lymphocapillary
anastomoses, which may contribute to the invasion ofcancer cells
into the vasculolymphatic system. Second. the ability of tumours
to grow at a metastatic site is dependent at least in part on neo-
vascularization (Folkman et al. 1990). Third. VEGF may facilitate
invasive potential by degrading the extracellular matrix through
plasminogen activation. Namely. VEGF is thought to induce plas-
minogen activator (PA) in vascular endothelial cells, which leads
to the conversion of plasminogen to plasmin (Pepper et al, 1991:
Mandriota et al. 1995). Plasmin in tum, activates a latent form
of the matrix metalloproteinases (MMPs) (Keski et al, 1992:
Montgomery et al, 1993; Baricos et al, 1995). Finally, VEGF
inhibits the functional maturation ofdendritic cells, which are the
most effective antigen-presenting cells in the induction ofprimary
immune responses (Gabrilovich et al, 1996), possibly leading to an
immunosuppressive state.
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With regard to regulation of VEGF production. hypoxia,
glucose deficiency and certain cytokines are supposed to up-regu-
late VEGF expression (Pertovaara et al, 1994; Li et al, 1995:
Shweiki et al, 1995; Cohen et al, 1996). Recently, Kieser et al
(1994) reported that mutant p53 up-regulated VEGF production
through the activation of protein kinase C. However, we did not
obtain a clear correlation between immunohistochemically
detected mutation of p53 and mRNA expression of VEGF (the
VEGF T/N ratio in p53 mutation negative samples; 4.32 ± 5.64 vs
p53 mutation-positive samples; 3.83 ± 4.10), although direct
sequencing of the p53 gene was not performed. Furthermore, no
significant correlation was seen between the expression of inter-
leukin 1, interleukin 6, transforming growth factor m and VEGF
(data not shown). Hereafter, more detailed studies are needed to
clarify the regulatory mechanism of VEGF expression in
colorectal cancer.
In the present study, we examined whether the levels of VEGF
mRNA expression in theprimary site ofcolorectal cancerfacilitate
prediction of patient prognosis or not. When the cut-off point of
the VEGF T/N ratio ranged from 2.8 to 12.0, the difference
between survivors and non-survivors was statistically significant.
To determine the optimal cut-offpoint ofthe VEGF T/N ratio, the
analytical method introduced by Miller and Siegmund (1982) was
used. Consequently. 4.8 was detenmined to be the optimal cut-off
point of the VEGF T/N ratio, and a tumour with this ratio
exceeding 4.8 was defined as demonstrating overexpression of
VEGF mRNA.
In the multivariate analysis, we selected three variables, depth
of tumour infiltration, tumour size and tumour differentiation,
other than the VEGF T/N ratio, because all ofthese variables have
been designated as putative prognostic factors based on conven-
tional histopathological studies ofprimary tumours. This analysis
revealed that expression intensity of VEGF mRNA was the most
reliable prognostic indicator among these factors.
Thus, we found that VEGF was associated with the progression,
and was presumably a significant participant in the metastatic
potential ofcolorectal cancer. These results suggest that the deter-
mination ofVEGF mRNA expression in colorectal cancermakes it
possible to predict post-operative patient prognosis and that the
VEGF T/N ratio can be used as an independent prognostic marker
in colorectal cancer patients.
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